Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.67 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.62 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.62 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.54 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219762 | 1.00 | ITPR3 (0.67) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL220555 | 1.00 | ITPR3 (0.67) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL19712146 | 0.98 | ITPR3 (0.65) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL5176539 | 0.98 | ITPR3 (0.65) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL14992390 | 0.96 | ITPR3 (0.61) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL11233751 | 0.93 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL7171543 | 0.93 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL4343592 | 0.93 | ITPR3 (0.74) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL4343591 | 0.93 | ITPR3 (0.74) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL6664274 | 0.93 | ITPR3 (0.74) | ITPR3ITPR1ITPR2INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260018347-A1 | FORMATION ELECTROLYTE FOR TANTALUM SOLID ELECTROLYTE CAPACITORS | KEMET ELECTRONICS CORP (US) | 2026-01-15 | — | — | US | claimed |
| WO-2024205856-A2 | IMPROVED FORMATION ELECTROLYTE FOR TANTALUM SOLID ELECTROLYTE CAPACITORS | KEMET ELECTRONICS CORPORATION (US) | 2024-10-03 | — | — | WO | claimed |
| US-20240331952-A1 | Formation Electrolyte for Tantalum Solid Electrolyte Capacitors | KEMET ELECTRONICS CORPORATION | 2024-10-03 | — | — | US | claimed |
| US-20210361680-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NORMOXYS INC (US) | 2021-11-25 | — | — | US | claimed |
| EP-3787634-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NormOxys, Inc. (US) | 2021-03-10 | — | — | EP | claimed |
| US-10159688-B2 | Methods and compositions for enhancing oxygen levels in tissues | M. ALPHABET 3, L.L.C. (US) | 2018-12-25 | — | — | US | claimed |
| US-20160346389-A1 | MODIFIED PARAMAGNETIC NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTICS AND METHODS THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2016-12-01 | — | — | US | claimed |
| US-20160038515-A1 | METHODS AND COMPOSITIONS FOR ENHANCING OXYGEN LEVELS IN TISSUES | M. ALPHABET 3., L.L.C. (US) | 2016-02-11 | — | — | US | claimed |
| EP-2968374-A1 | METHODS AND COMPOSITIONS FOR ENHANCING OXYGEN LEVELS IN TISSUES | M. Alphabet 3 LLC (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015038924-A1 | MODIFIED PARAMAGNETIC NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTICS AND METHODS THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-03-19 | — | — | WO | claimed |
| EP-1863495-B1 | CALCIUM AND SODIUM SALT OF MYO-INOSITOL 1,6:2,3:4,5 TRIPYROPHOSPHATE FOR TREATING CANCER | NORMOXYS INC (US) | 2015-02-18 | — | — | EP | claimed |
| WO-2014145037-A1 | METHODS AND COMPOSITIONS FOR ENHANCING OXYGEN LEVELS IN TISSUES | M. ALPHABET 3, L.L.C. (US) | 2014-09-18 | — | — | WO | claimed |
| EP-1863495-A1 | CALCIUM SALT OF MYO-INOSITOL 1,6:2,3:4,5 TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN | Oxyplus, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060241086-A1 | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin | NORMOXYS, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006102060-A1 | CALCIUM SALT OF MYO-INOSITOL 1,6:2,3:4,5 TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN | OXYPLUS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20260018347-A1 | FORMATION ELECTROLYTE FOR TANTALUM SOLID ELECTROLYTE CAPACITORS | KEMET ELECTRONICS CORP (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4518842-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20070135389-A1 | calcium and sodium mixed salt of inositol tripyrophosphate; anticancer | NORMOXYS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20060241086-A1 | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin | NORMOXYS, INC. | 2006-10-26 | — | — | US | disclosed |
| WO-2006102060-A1 | CALCIUM SALT OF MYO-INOSITOL 1,6:2,3:4,5 TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN | OXYPLUS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240331952-A1 | Formation Electrolyte for Tantalum Solid Electrolyte Capacitors | ITPR1, ITPR3, ITPR2 | ITPR3 2/4885ITPR1 1/4885ITPR2 3/4885 |
| US-20060241086-A1 | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin | ITPR3, ITPR1, ITPR2 | ITPR3 1/4885ITPR1 2/4885ITPR2 3/4885 |
| US-20160038515-A1 | METHODS AND COMPOSITIONS FOR ENHANCING OXYGEN LEVELS IN TISSUES | PLCB3, INPP5B, PLCG2 | ITPR3 13/4885ITPR1 21/4885ITPR2 26/4885 |
| US-20260018347-A1 | FORMATION ELECTROLYTE FOR TANTALUM SOLID ELECTROLYTE CAPACITORS | ITPR2, SLC9A2, ITPR3 | ITPR3 3/4885ITPR1 4/4885ITPR2 1/4885 |
| US-10159688-B2 | Methods and compositions for enhancing oxygen levels in tissues | PLCB3, INPP5B, PLCG2 | ITPR3 13/4885ITPR1 21/4885ITPR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.